Trial Profile
An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Topotecan (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 19 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
- 18 Nov 2006 New trial record.